A new drug created by Chinese CStone Pharmaceuticals and EQRx offers a low-cost alternative in the crowded lung cancer chemotherapy space. Checkpoint inhibitor sugemalimab has led to promising results in Phase 3 clinical trials and its manufacturers are now pursuing international regulatory approval. The companies formed a partnership with the overall goal of undercutting existing therapies offered by other pharmaceutical companies.
EQRx CEO Alexis Borisy remarks, “[The] market is becoming more crowded, but the constant debate around pricing without action is to the detriment of patients.” Read more here.
(Source: Ben Fidler, Healthcare Dive, 6/2/21)